arrow
S

Suvi Sorsa

university of helsinki
H指数:16
被引数:1,040

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Effects of Concomitant Medications on Clinical and Immunological Outcomes of Cancer Patients Treated With Oncolytic Adenoviruses

溶瘤腺病毒治疗癌症患者时联合用药对临床和免疫学结局的影响

2026-11-020
OAAI
Single intravenous administration of oncolytic adenovirus TILT-123 results in systemic tumor transduction and immune response in patients with advanced solid tumors

单次静脉注射溶瘤腺病毒TILT-123可导致晚期实体瘤患者的全身肿瘤转导和免疫反应

2024-11-060
OAAI
Effective intravenous delivery of adenovirus armed with TNFα and IL-2 improves anti-PD-1 checkpoint blockade in non-small cell lung cancer

有效静脉注射tnf α 和IL-2腺病毒可改善非小细胞肺癌的anti-PD-1检查点阻滞

2023-08-0211
OA
Oncolytic adenovirus coding for bispecific T cell engager against human MUC-1 potentiates T cell response against solid tumors

溶瘤腺病毒编码针对人类MUC-1的双特异性T细胞接合器增强T细胞对实体瘤的反应

2023-03-017
OAAI
Development of a Syrian hamster anti-PD-L1 monoclonal antibody enables oncolytic adenoviral immunotherapy modelling in an immunocompetent virus replication permissive setting

叙利亚仓鼠anti-PD-L1单克隆抗体的开发使溶瘤腺病毒免疫疗法能够在免疫能力病毒复制允许的环境中进行建模

2023-02-034
OAAI
Adenovirus Encoding Tumor Necrosis Factor Alpha and Interleukin 2 Induces a Tertiary Lymphoid Structure Signature in Immune Checkpoint Inhibitor Refractory Head and Neck Cancer
2022-03-0728
OAAI
Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses

间皮素重定向的嵌合抗原受体T细胞和细胞因子武装的溶瘤腺病毒联合治疗胰腺癌

2018-04-05220
OAAI